Benzinga | Apr 8, 2021 07:34AM EDT

Teva Canada Announces New Autoinjector for AJOVY for the Preventive Treatment of Migraine in Adults

AJOVY(r) now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe

* AJOVY(r) is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults.

* AJOVY(r) is supported by the AJOVY(r) Teva Support Solutions(r) (AJOVY(r) TSS) Patient Support Program, whose services include reimbursement navigation, bridging/copay coverage, and injection training.

* AJOVY(r) has been studied in patients with either chronic or episodic migraine and was shown to significantly reduce patients' mean monthly migraine days--with some patients achieving a 50% reduction or more.